Trial
NCT04161391
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Turning Point Therapeutics, Inc.
Collaborators
—
Condition
Non Small Cell Lung Cancer
Intervention
TPX-0046
Why stopped
Adverse change in the risk/benefit.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-06-13